Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) has filed its Monthly Return for the period ended 30 April 2026, indicating stable share capital and no issuance activity during the month.

Authorised and Issued Share Capital • Authorised / registered share capital remained unchanged at RMB 3.71 billion, split between 919.07 million H shares and 2.79 billion A shares, each with a par value of RMB 1.00.

• Issued shares were also unchanged:  – H shares: 919.07 million, all in public float and fully compliant with Hong Kong’s 5% minimum float requirement for PRC issuers.  – A shares: 2.79 billion.

Treasury Shares • The company held no treasury shares at either the beginning or end of April, and recorded no movements during the month.

Share-Based Incentives • All 0.68 million reserved options under the A-share option scheme (exercise price: RMB 20.16) were cancelled, reducing outstanding options to zero. • No shares were issued and no funds were raised from option exercises.

Other Instruments • The report shows no warrants, convertible securities, or other equity-linked instruments outstanding or transacted during the period.

Regulatory Compliance • SH PHARMA confirmed adherence to all listing and regulatory requirements, including public float, documentation, and settlement obligations.

Net Effect • Total increase or decrease in issued shares for April 2026: nil. • Total increase or decrease in treasury shares: nil.

The filing underscores a month of capital stability for SH PHARMA, with the only notable action being the cancellation of the remaining A-share options, effectively closing that incentive program.